Healthcare Sales & Marketing Network News: interleukin

Searching News Database: interleukin

HSMN NewsFeed - 25 Feb 2026
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Jul 2025
Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx(R) in Giant Cell Arteritis (GCA)
Biopharmaceuticals

HSMN NewsFeed - 31 Mar 2025
Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 10 Feb 2025
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 7 Feb 2025
Most Patients on Lilly's Omvoh(R) (mirikizumab-mrkz) for Crohn's Disease Achieved Sustained Clinical Remission and Endoscopic Response at Two Years
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 31 Jan 2025
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 16 Jan 2025
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX(R) (bimekizumab-bkzx)
Biopharmaceuticals Drug Delivery Product Launch

HSMN NewsFeed - 25 Oct 2024
Lilly's EBGLYSS(TM) (lebrikizumab-lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab
Biopharmaceuticals Dermatology

HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Aug 2024
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 20 Nov 2023
FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Oct 2023
FDA Approves Novartis Cosentyx(R) as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Sep 2023
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Apr 2023
Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 19 Sep 2022
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI(R)) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 7 Jun 2022
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Biopharmaceuticals Dermatology

HSMN NewsFeed - 24 May 2022
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 10 May 2022
Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board
Regenerative Medicine Orthopaedic Venture Capital

HSMN NewsFeed - 29 Apr 2022
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing

HSMN NewsFeed - 17 Dec 2021
OncoSec Announces Changes to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Nov 2021
Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
Biopharmaceuticals

HSMN NewsFeed - 20 Oct 2021
FDA Expands Approval of Dupixent(R) (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Sep 2021
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology
Biopharmaceutical Gastroenterology Personnel

HSMN NewsFeed - 13 Aug 2021
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Biopharmaceuticals

HSMN NewsFeed - 9 Aug 2021
SKYRIZI(R) (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Product Launch

HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 14 Jun 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 May 2021
Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Apr 2021
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse(TM)" for the Treatment of Solid Tumors
Devices Oncology Regulatory

HSMN NewsFeed - 15 Mar 2021
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Feb 2021
OncoSec Strengthens Management Team With Two New Appointments
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Jan 2021
Connect Biopharma Strengthens Leadership Team with Key Hire
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Jan 2021
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 23 Nov 2020
Rigel and Medison Announce Health Canada Approval of TAVALISSE(R), an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 24 Jul 2020
Bimekizumab Superior to Cosentyx(R) in Achieving Complete Psoriasis Skin Clearance
Biopharmaceuticals Dermatology

HSMN NewsFeed - 17 Jul 2020
Lilly's Mirikizumab Superior to Cosentyx(R) (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jun 2020
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA

HSMN NewsFeed - 30 Mar 2020
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 8 Jan 2020
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 15 Nov 2019
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Biopharmaceuticals Regulatory

HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals

HSMN NewsFeed - 3 Oct 2019
New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Aug 2019
Dupixent(R) (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Jun 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals

HSMN NewsFeed - 14 Jun 2019
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Biopharmaceuticals

HSMN NewsFeed - 11 Jun 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz(R) (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Biopharmaceuticals Dermatology

HSMN NewsFeed - 7 May 2019
Dupixent(R) (dupilumab) Approved for Severe Asthma by European Commission
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 1 Apr 2019
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 26 Mar 2019
AbbVie Announces First Regulatory Approval of SKYRIZI(TM) (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Mar 2019
CHMP Recommends Approval of Dupixent(R) (dupilumab) for Asthma Indication
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Mar 2019
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 7 Jan 2019
Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Dec 2018
OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2018
OncoSec Appoints Robert Ward to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Oct 2018
FDA Approves Asthma Indication for Dupixent(R) (dupilumab)
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals

HSMN NewsFeed - 4 Sep 2018
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 28 Aug 2018
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Jul 2018
OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals

HSMN NewsFeed - 16 May 2018
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 10 May 2018
Lilly Announces Agreement To Acquire ARMO BioSciences
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals

HSMN NewsFeed - 16 Jan 2018
Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Biopharmaceuticals Dermatology

HSMN NewsFeed - 25 Dec 2017
I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Biopharmaceuticals Gastroenterology Personnel

HSMN NewsFeed - 12 Dec 2017
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Dec 2017
Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Nov 2017
Sobi(TM) - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Still's Disease
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals

HSMN NewsFeed - 12 Oct 2017
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Biopharmaceuticals Dermatology

HSMN NewsFeed - 15 Sep 2017
Janssen Receives CHMP Positive Opinion for Guselkumab Recommending Approval for the Treatment of Moderate to Severe Plaque Psoriasis in the European Union
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 29 Aug 2017
ARMO BioSciences Raises $67 Million in a Series C-1 Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 27 Jul 2017
Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Biopharmaceuticals Dermatology Product Launch

HSMN NewsFeed - 17 Jul 2017
Medicenna Bolsters Management Team
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals

HSMN NewsFeed - 8 Jun 2017
Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 May 2017
Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 21 Apr 2017
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ(TM) (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 27 Mar 2017
Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Feb 2017
Kevzara(TM) (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Product Launch

HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 24 Jan 2017
FDA Grants Priority Review for Genentech’s Actemra(R) (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 14 Dec 2016
Health Canada approves STELARA(R) for the treatment of adults with moderately to severely active Crohn's disease
Biopharmaceuticals Gastroenterology Regulatory

HSMN NewsFeed - 9 Dec 2016
Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA(TM) (Daclizumab Beta) for Multiple Sclerosis
Biopharmaceuticals Nerurology Regulatory

HSMN NewsFeed - 7 Oct 2016
Rigel Expands Leadership Team in Research and Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Oct 2016
Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 8 Jul 2016
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Jul 2016
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 1 Jul 2016
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
Biopharmaceuticals Licensing

HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Apr 2016
European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix(TM), XBiotech’s True Human(TM) Therapeutic Antibody Treatment for Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Biopharmaceuticals

HSMN NewsFeed - 26 Feb 2016
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 25 Jan 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Sep 2015
Valeant And AstraZeneca To Partner On Brodalumab
Biopharmaceuticals Dermatology Licensing Distribution

HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 11 Aug 2015
Celgene Receives Antitrust Clearance for Receptos Acquisition
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 8 Sep 2014
Successful Completion of Phase III Program for Teva’s Reslizumab Two More Phase Iii Studies Support the Benefits of Reslizumab Treatment in Asthma Patients with Eosinophilia
Biopharmaceuticals

HSMN NewsFeed - 29 Jul 2014
Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing

HSMN NewsFeed - 13 Dec 2013
Neumedicines Presents HemaMax(TM) Clinical Data at the ASH Conference
Biopharmaceuticals

HSMN NewsFeed - 4 Dec 2013
TherapeuticsMD Appoints Joel S. Krasnow, M.D. as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Nov 2013
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Biopharmaceuticals

HSMN NewsFeed - 22 Jul 2013
Receptos Announces Appointment of Erle T. Mast as Director
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA

HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Sep 2012
EpiCept Regains Rights to Azixa(R) from Licensee Myrexis
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 14 Dec 2011
Interleukin Genetics Appoints Lynn Doucette-Stamm Vice President of Development
Diagnostics Personnel

HSMN NewsFeed - 7 Jun 2011
XOMA Appoints Paul Rubin, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Apr 2011
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Mar 2011
EpiCept Identifies Ceplene(R) Survival Benefit in Key AML Subgroup
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Jan 2011
FDA Grants Supplemental Approval for ACTEMRA(R) (tocilizumab)
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Dec 2010
EpiCept Announces Ceplene(R) Approved for Marketing in Israel
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 28 Oct 2010
EpiCept Corporation and FDA Agree on Development Plan for Ceplene(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology

HSMN NewsFeed - 23 Jul 2010
Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA(R) Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 19 Jul 2010
Phage Pharmaceuticals Appoints David Jackson as Vice President, Operations Planning
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Jun 2010
Galera Therapeutics Secures Funding for New Cancer Treatment
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 7 Jun 2010
Cytheris Closes 12 Million ($15 Million) Series D Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 May 2010
EpiCept Corporation Announces Commercial Launch of Ceplene(R) in Germany
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 19 Apr 2010
EpiCept Announces Commercial Launch of Ceplene(R) in the United Kingdom
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Mar 2010
Genentech Submits Supplemental Biologics License Application for ACTEMRA(R) (tocilizumab) for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Mar 2010
FDA Advisory Committee Recommends Approval of Belatacept, an Investigational Agent for Prophylaxis of Acute Rejection in De Novo Kidney Transplant Patients
Biopharmaceuticals

HSMN NewsFeed - 26 Jan 2010
Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 14 Jan 2010
STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 11 Jan 2010
EpiCept Announces Commercial Licensing Agreement for Ceplene(R) with Meda in Europe and Pacific Rim
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 9 Jan 2010
FDA Approves ACTEMRA(R) (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Nov 2009
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
Biopharmaceuticals

HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 24 Jul 2009
Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals Regulatory

HSMN NewsFeed - 10 Jul 2009
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 May 2009
Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
Biopharmaceuticals

HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 13 Jan 2009
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Biopharmaceuticals

HSMN NewsFeed - 8 Jan 2009
TOPIGEN Pharmaceuticals Reports Phase 2 Results of TPI ASM8 in Asthma Patients
Biopharmaceuticals

HSMN NewsFeed - 4 Dec 2008
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2008
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Biopharmaceuticals

HSMN NewsFeed - 9 Oct 2008
EpiCept Receives Ceplene(R) Marketing Approval in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 1 Oct 2008
Alnylam Appoints Industry Leader John Schmidt as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 3 Sep 2008
DiaKine Therapeutics Announces Financing and New Board Member
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 8 Aug 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
Biopharmaceuticals FDA

HSMN NewsFeed - 5 Aug 2008
Curacyte Sells Its Subsidiary Curacyte Discovery GmbH to The Medicines Company
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Aug 2008
The Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Aug 2008
TVM Capital Welcomes The Medicines Company in The European Market Through the Acquisition of Curacyte Discovery GmbH
Biopharmaceuticals Venture Capital Mergers & Acquisitions

HSMN NewsFeed - 4 Aug 2008
Expression Genetics Inc., Specializing in DNA/RNAi Delivery and Therapeutics, Completes $12M Series B Financing
Biopharmaceuticals Drug Delivery Venture Capital

HSMN NewsFeed - 25 Jul 2008
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Biopharmaceuticals Regulatory Oncology

HSMN NewsFeed - 17 Jun 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Jun 2008
ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
Biopharmaceuticals

HSMN NewsFeed - 12 Jun 2008
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2008
EpiCept Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Apr 2008
Stemline Therapeutics Raises $12.5 Million
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 25 Mar 2008
ARCALYST(TM) (rilonacept), First and Only FDA-approved Treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), Now Available in the United States
Biopharmaceuticals

HSMN NewsFeed - 20 Mar 2008
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Biopharmaceuticals

HSMN NewsFeed - 20 Mar 2008
EpiCept Announces Opinion by European Regulatory Authority on Ceplene(R)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Feb 2008
FDA Approves Regeneron's ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals FDA

HSMN NewsFeed - 12 Feb 2008
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
Biopharmaceuticals Licensing

HSMN NewsFeed - 11 Feb 2008
SciClone and Sigma-Tau Report Promising Interim Results From Phase 3 Hepatitis C Trial
Biopharmaceuticals

HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 20 Dec 2007
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate
Biopharmaceuticals

HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine

HSMN NewsFeed - 10 Dec 2007
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Dec 2007
AVAX Technologies Appoints Dr. Francois Martelet as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Dec 2007
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 26 Nov 2007
Cytheris Appoints Richard Keatinge as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 Nov 2007
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 19 Nov 2007
The Aethlon Hemopurifier(R) Reverses Immune Suppression in Cancer
Devices Oncology

HSMN NewsFeed - 14 Nov 2007
Protox collaborates with BrainLAB for Brain Cancer Program
Devices Neurosurgery

HSMN NewsFeed - 13 Nov 2007
AVAX Technologies announces the initiation of its Phase III Registration trial of M-Vax(R) in Metastatic Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Nov 2007
Lodotra(TM) Shows a Sustained Reduction of Morning Stiffness in Patients with Rheumatoid Arthritis Treated with Lodotra(TM) for 12 Months
Biopharmaceuticals

HSMN NewsFeed - 25 Oct 2007
Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Oct 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 3 Oct 2007
Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
Biopharmaceuticals

HSMN NewsFeed - 8 Aug 2007
Rilonacept (IL-1 Trap) Granted FDA Priority Review for the Treatment of CAPS
Biopharmaceuticals

HSMN NewsFeed - 25 Jul 2007
Fourth ACTEMRA(TM) (tocilizumab) Phase III Study Demonstrates Significant Clinical Benefit in RA Patients
Biopharmaceuticals

HSMN NewsFeed - 10 Jul 2007
ACTEMRA(TM) (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 2 Jul 2007
ZymoGenetics Announces Senior Management Promotions
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Jun 2007
ACTEMRA(TM) (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2007
Latest Data Show MabThera(R) Provides Significant and Sustained Relief From Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 8 Jun 2007
Regeneron Submits Biologics License Application to U.S. FDA for IL-1 Trap (Rilonacept) for Treatment of CAPS
Biopharmaceuticals

HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
ONTAK(R) (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jun 2007
Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 May 2007
Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 14 Apr 2007
ARIAD files claim against Amgen and Wyeth Alleging Infringement of NF-(kappa)B Patent by Enbrel(R) and Kineret(R)
Biopharmaceuticals Litigation

HSMN NewsFeed - 12 Apr 2007
XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 10 Apr 2007
Genaera Corporation Names New Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Mar 2007
Stemline Therapeutics In-Licenses Phase I Oncology Compound
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 24 Jan 2007
Phase III ACTEMRA(TM) (tocilizumab) Study Results Demonstrate Significant Improvement in Signs and Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 16 Jan 2007
CEL-SCI Receives Green Light From FDA to Proceed With Phase III Cancer Study
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Jan 2007
Bayer and Onyx Announce Pivotal Nexavar(R) Kidney Cancer Study Published in New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jan 2007
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jan 2007
Genaera Corporation Terminates EVIZON(TM) Clinical Program and Restructures
Biopharmaceuticals Ophthalmology

HSMN NewsFeed - 14 Dec 2006
Quest Diagnostics Launches Test to Help Oncologists Predict Risk of Breast Cancer Recurrence in Women with Estrogen Receptor (ER)-Positive, Lymph Node- Negative Cancers
Diagnostics Oncology

HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals

HSMN NewsFeed - 13 Nov 2006
New Study Shows ACTEMRA(TM) (tocilizumab) Significantly Improves Remission Rates in Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine

HSMN NewsFeed - 1 Nov 2006
EpiCept Announces Successful Validation of Marketing Authorization Application for Ceplene(TM)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Oct 2006
Amgen Completes Acquisition of Avidia
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 16 Oct 2006
Genaera Presents New EVIZON(TM) Safety Data at the Angiogenesis Foundation 4th Annual International Conference
Biopharmacetuicals Ophthalmology

HSMN NewsFeed - 9 Oct 2006
EpiCept Files for Marketing Approval of Ceplene(TM) in European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 29 Sep 2006
Amgen to Acquire Avidia, a Privately Held Biopharmaceutical Company in the San Francisco Bay Area
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 18 Sep 2006
NEOPHARM Presents Updated CINTREDEKIN BESUDOTOX Phase I/II Median Survival Data at European Association of Neuro-Oncology (EANO) Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jun 2006
NeoPharm Announces PRECISE Trial Update
Biopharmaceuticals Drug Delivery Neurosurgery Oncology

HSMN NewsFeed - 31 May 2006
Regeneron Receives Fast-Track Designation for the IL-1 Trap in CIAS1-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals FDA

HSMN NewsFeed - 23 May 2006
CEL-SCI Presents Long-Term Survival Data With Its Anti-Cancer Drug Multikine(R)
Biopharmaceuticals Oncology

Return to NewsFeed

Additional items found! 134

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 134 additional stories matching:
interleukin
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!